Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:lamotrigine
|
| gptkbp:approvalYear |
2009
|
| gptkbp:ATCCode |
gptkb:N03AX09
|
| gptkbp:brand |
gptkb:lamotrigine
|
| gptkbp:contraindication |
hypersensitivity to lamotrigine
|
| gptkbp:drugClass |
anticonvulsant
mood stabilizer |
| gptkbp:form |
extended-release tablet
|
| gptkbp:halfLife |
25-33 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lamictal XR
|
| gptkbp:indication |
bipolar disorder
epilepsy |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
sodium channel blocker
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:regulates |
approved
|
| gptkbp:riskFactor |
gptkb:toxic_epidermal_necrolysis
gptkb:Stevens-Johnson_syndrome serious skin rashes |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache rash insomnia |
| gptkbp:usedFor |
partial seizures
primary generalized tonic-clonic seizures maintenance treatment of bipolar I disorder |
| gptkbp:bfsParent |
gptkb:lamotrigine
|
| gptkbp:bfsLayer |
7
|